Dividends & Buybacks ·
Enlivex proposes reverse split between 1-for-13 and 1-for-16 to meet Nasdaq's $1 minimum bid price requirement
ENLVEnlivex Ltd.
Enlivex Ltd. filed an amendment to its Form 6-K to update proxy materials for an Extraordinary General Meeting of Shareholders scheduled for October 16, 2026. The primary proposal seeks shareholder approval for a reverse share split of ordinary shares at a ratio between 1-for-13 and 1-for-16, with the Board authorized to select the final ratio within this range. Additionally, shareholders are asked to authorize the Board to effect one or more additional reverse splits within 12 months, with an aggregate ratio ranging from 1-for-2 to 1-for-1,000. The company states these actions aim to increase the share price to meet Nasdaq's minimum bid price requirement of $1.00 per share and avoid potential delisting. Enlivex Ltd. operates in the biotechnology industry, focusing on developing cancer immunotherapies.